Page 323 - Drug Class Review

Drug Effectiveness Review Project
Groups similar at baseline: No (more females in high dose RIV group)
Alzheimer classification: Mild-moderate

Health Outcome Measures:

placebo rivastigmine (6-12 mg/d) rivastigmine (1-4 mg/d) 73.8 74.9 74.8 68 57 58 97% 95% 94% 3% 4% 4% 0% 1% 2% 19.62 19.5 20 47% 47% 44% Primary Outcome Measures: ADAS-Cog; CIBIC-plus; PDS (all stratified by baseline MHIS score category; MHIS > 0 means VRF are present) Secondary Outcome Measures: MMSE; GDS (all stratified by baseline MHIS score category) Timing of assessments: Baseline, and weeks 12, 18 and 26 or early termination Treatment differences in PDS scores between high dose RIV and placebo were greater in the

• • • • •

Final Report Update 1 Authors: Kumar et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Mean MMSE score • % with MHIS > 0 (VRF) • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs